Abbott Laboratories stock holds valuation premium amid steady earnings
Published on 09/07/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories stock (ISIN US0028241000) continues to command a valuation premium, with a trailing price-to-earnings ratio around 35.05 based on recent market data as of early September 2026, underlining investors' willingness to pay up for its diversified healthcare earnings stream.
Earnings support current valuation
Abbott Laboratories, a global healthcare group focused on diagnostics, medical devices, nutrition and branded generics, has in recent quarters delivered steady revenue and earnings growth that helps justify the stock's elevated valuation multiples.
According to recent market and fundamental overviews that benchmark Abbott Laboratories against other large-cap US healthcare peers, the company is trading at a price-to-book ratio of about 3.68 and a PEG ratio close to 1.99, indicating that projected earnings growth is broadly in line with its current premium pricing.
Valuation compared with peers
In comparative data that list Abbott Laboratories alongside other US-listed names, the company's trailing P/E of 35.05 stands noticeably above many diversified industrials and financials, but is more in line with quality growth healthcare stocks where investors prioritize earnings visibility and pipeline strength.
The PEG ratio near 1.99 suggests that, while Abbott Laboratories is not trading at a deep discount to its expected growth rate, the market is not excessively overpaying either when growth-adjusted metrics are considered.
Product portfolio remains central
A core pillar of Abbott Laboratories' investment story remains its broad portfolio across diagnostics systems, cardiovascular and diabetes devices, as well as nutritional products, which together generate recurring revenue and underpin the company's earnings stability.
For investors, the balance between mature, cash-generating franchises and newer technology-driven solutions in areas such as continuous glucose monitoring is a key factor when assessing whether the current valuation around a trailing P/E of 35.05 is warranted.
Stock perspective for investors
With Abbott Laboratories stock trading on valuation metrics that reflect its role as a quality growth healthcare name, the current multiples around a P/E of 35.05, price-to-book of 3.68 and PEG of 1.99 as of early September 2026 highlight how the market prices in both its diversified earnings base and future expansion opportunities.
Abbott Laboratories stock at a glance
- Company: Abbott Laboratories Inc.
- ISIN: US0028241000
- Ticker: ABT
- Trading venue: NYSE
- Sector / Industry: Health Care / Medical Devices and Diagnostics
- Index membership: S&P 500
